Martins B

Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.

1 preprint · 6 papers · ORCID

PreprintPsilocybin

Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial

Kelmendi B, Adams T, Ching THW +16

Europe PMC2026
ArticlePsilocybin

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.

Ching THW, Stahnke B, Shnayder S +22

Europe PMC2025
ArticlePsychedelics

The library is open: a scoping review on queer representation in psychedelic research.

Bartlett A, Christ C, Martins B +2

Europe PMC2024
ArticlePsilocybin

Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.

Ching THW, Amoroso L, Bohner C +16

Europe PMC2024
ArticlePsilocybin

Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.

Ching THW, Amoroso L, Bohner C +15

Europe PMC2023
ArticlePsilocybin

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.

Ching THW, Grazioplene R, Bohner C +14

Europe PMC2023
ArticleKetamine

Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders.

Martins B, Rutland W, De Aquino JP +4

Europe PMC2022